Pfizer Inc. (NYSE:PFE) ‘s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimers disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20%and weekly performance is 2.06%. On last trading day company shares ended up $29.66. Analysts mean target price for the company is $33.97. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -2.98%.
Johnson & Johnson (NYSE:JNJ), is building on a 28-year history in the country. Device sales grew 18 percent in China to $1.4 billion in 2013, said Chief Financial Officer Dominic Caruso. Johnson & Johnson (NYSE:JNJ) hasn’t experienced issues such as the indictment of a GlaxoSmithKline executive in a bribery probe and the fines leveled against infant formula companies for price fixing. Johnson & Johnson (NYSE:JNJ) shares advanced 0.52% in last trading session and ended the day on $100.96. JNJ Gross Margin is 69.10%and its return on assets is 11.90%. Johnson & Johnson (NYSE:JNJ) quarterly performance is 11.08%.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was graded by equities researchers at Roth Capital from a “buy” rating to a “neutral” rating in a research report issued on Tuesday, They currently have a target price on the stock, down from their previous target price. Roth Capital’s price target would indicate a potential upside of 3.37% from the stock’s previous close.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares moved up 0.15% in last trading session and was closed at $6.54, while trading in range of $6.53 – $6.58. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) year to date (YTD) performance is 47.63%.
On 21 May Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported quarter results, the total revenue rose 82% to $11.8M & it included $8 million of sales of the company’s leukemia drug-Iclusig that had been temporarily pulled out from the market towards the end of 2013 for a few weeks & had been relabeled with some more inclusive safety-warnings. This is a 25% rise from the previous year. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended the last trading day at $6.34. Company weekly volatility is calculated as 4.21% and price to cash ratio as 4.99. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a negative weekly performance of -2.46%.
On 19 MAY Merck & Co., Inc. (NYSE:MRK) announced the withdrawal of conditional marketing authorization applications from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).Merck & Co., Inc. (NYSE:MRK) net profit margin is 14.00%and weekly performance is 1.07%. On last trading day company shares ended up $56.49. Analysts mean target price for the company is $59.22. Merck & Co., Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 0.24%.